Sugi Predict

Sugi Predict / Compounds / SCHEMBL4096175

SCHEMBL4096175

SCHEMBL4096175

O=C(Nc1cccc([N+](=O)[O-])c1)NC(c1ccc(C(=O)Nc2nn[nH]n2)cc1)c1ccc(C2=CCCCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAT2 Q10469 2/20 0.40
▸ MEN1 O00255 9/20 0.40
▸ KMT2A Q03164 9/20 0.40
▸ RAB9A P51151 5/20 0.40
▸ LMNA P02545 4/20 0.39
▸ MAPT P10636 5/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ BAZ1A Q9NRL2 1/20 0.39
▸ POLB P06746 3/20 0.38
▸ DDX3X O00571 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087840 0.86 MGAT2 (0.45) MGAT2SMN1; SMN2KDM4E
SCHEMBL4091306 0.85 MGAT2 (0.42) MGAT2MEN1KMT2ALMNAALDH1A1
SCHEMBL4082123 0.84 GCGR (0.47) MGAT2
SCHEMBL4097437 0.84 S1PR2 (0.40) MGAT2MEN1KMT2ARAB9ALMNA
SCHEMBL4091781 0.84 GCGR (0.43) MGAT2LMNA
SCHEMBL4081065 0.84 MEN1 (0.59) MEN1KMT2ARAB9ALMNAMAPT
SCHEMBL4091878 0.83 RAB9A (0.45) MEN1KMT2ARAB9ALMNAMAPT
SCHEMBL4096168 0.82 GCGR (0.52) MGAT2MEN1KMT2ARAB9AALDH1A1
SCHEMBL4091869 0.82 ABCG2 (0.46) MEN1KMT2ARAB9ALMNAMAPT
SCHEMBL2652468 0.81 GCGR (0.50) MEN1KMT2ARAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR MGAT2 149/4885MEN1 2079/4885KMT2A 3304/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR MGAT2 149/4885MEN1 2079/4885KMT2A 3304/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR MGAT2 149/4885MEN1 2079/4885KMT2A 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.